Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Rossi

Showing results (401-410 of 504) with videos related to

Pageof 51
Sort By:
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
American Journal of Hematology|July 10, 2018
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 casesFortunato Morabito, Tait D Shanafelt, Massimo Gentile, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Haematologica|July 29, 2017
Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemiaPietro Bulian, Riccardo Bomben, Michele Dal Bo, et al.
British Journal of Haematology|November 28, 2008
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Cancer|September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patientsAlessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
Pageof 51

Showing results (401-410 of 504) with videos related to

Sort By:
Pageof 51
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
American Journal of Hematology|July 10, 2018
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 casesFortunato Morabito, Tait D Shanafelt, Massimo Gentile, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Haematologica|July 29, 2017
Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemiaPietro Bulian, Riccardo Bomben, Michele Dal Bo, et al.
British Journal of Haematology|November 28, 2008
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Cancer|September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patientsAlessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
Pageof 51